Pathos
PrivateLast Round
Series E
Oct 23, 2026
Est. Valuation
$3B
Total Funding Raised
$704M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Pathos is a biotechnology company that utilizes an AI-enabled drug discovery platform to accelerate the development of precision oncology therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathos Comparables
Compare Pathos with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 88% | |
| BenevolentAI | 83% | |
| Chai Discovery | 81% |
For institutional investors. Book with your work email.
Pathos Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Oct 23, 2026 | ||||
| Series D | May 15, 2025 | ||||
| Series C | Oct 29, 2024 | ||||
| Series B | Mar 2, 2023 | ||||
| Series A | Jul 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pathos Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Builders VC | Series C, Series B, Series E, Series A |
| Lightbank | Series C, Series B, Series E, Series A |
| New Enterprise Associates | Series B, Series E, Series A, Series C |
| Revolution Ventures | Series C |
| Revolution Growth | Series C, Series E, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 23, 2026
$300M round at $3B valuation.
- Apr 1, 2026
AI drug development platform Foundry is now live and in production.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 26, 2026
Bristol-Myers Squibb Co is to gain access to Pathos's Foundry AI platform, including exclusive rights for neuroscience development programs over three years, under the collaboration announced on Oct 29th '26.
- is_developingOct 23, 2026
Pathos announces partnerships with Bristol Myers Squibb and Tempus AI to develop AI tools and a patient dataset for research into Alzheimer's and other neurological diseases on Oct 23rd '26.
- receives_financingOct 23, 2026
On Oct 23rd '26, Pathos receives $237M in Series E financing led by Bristol Myers Squibb, with participation from existing investors, to develop its platform and advance its experimental-drug pipeline in New York.
- partners_withOct 23, 2026
On Oct 23rd '26, Pathos partners with Bristol-Myers Squibb Co and Tempus AI to harness artificial intelligence in developing treatments for Alzheimer's disease and other neurological disorders.
- partners_withOct 23, 2026
On Oct 23rd '26, Pathos partners with Tempus to harness artificial intelligence in developing treatments for Alzheimer's disease and other neurological disorders.
For institutional investors. Book with your work email.
Pathos Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pathos's valuation, stock price, and market status.
Is Pathos a public or private company?
Pathos is a private company.
What is the current stock price of Pathos?
Pathos is a private company, so its shares have no public market price. Caplight tracks Pathos's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pathos worth (valuation)?
Pathos's valuation is estimated at $3.0B based on funding round data.
Can I buy Pathos stock?
Pathos shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pathos's last funding round?
Pathos's most recent funding round was Series E on October 23, 2026.
Who are the main investors in Pathos?
Key investors in Pathos include New Enterprise Associates.
Will Pathos IPO soon?
No public IPO plans have been announced for Pathos.
How can I track Pathos secondary market activity?
Caplight tracks bids, offers, and trades in Pathos's shares on secondary markets.